drugset / Trial / NCT02362165
CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
Bortezomib-based triple-drug combination has greatly improved the response rate of multiple myeloma patients. Bortezomib,doxorubicin,and dexamethasone (PAD) is commonly used in clinical practice.Recent studies have found that cyclophosphamide, bortezomib,and dexamethasone (CyBorD)seems better than PAD in efficacy. However, there is no randomized phase 3 trial comparing these two regimens in the treatment of newly diagnosed multiple myeloma patients.In this study, the investigators will compare the efficacy and safety of these two regimens using once-weekly subcutaneous injection of bortezomib.
Timeline
- Start
- 2015-04
- Primary completion
- 2018-04
- Completion
- 2018-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Subject | Cyclophosphamide | Other / unclassified | 500 mg | Oral |
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Comparator | Doxorubicin | Other / unclassified | 9 mg/m2 | — |